Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Statistics

Total Valuation

Kairos Pharma has a market cap or net worth of $12.64 million. The enterprise value is $7.97 million.

Market Cap	12.64M
Enterprise Value	7.97M

Important Dates

The next estimated earnings date is Wednesday, May 13, 2026, before market open.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Kairos Pharma has 21.41 million shares outstanding. The number of shares has increased by 62.27% in one year.

Current Share Class	21.41M
Shares Outstanding	21.41M
Shares Change (YoY)	+62.27%
Shares Change (QoQ)	+3.18%
Owned by Insiders (%)	36.51%
Owned by Institutions (%)	8.13%
Float	12.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.91
P/TBV Ratio	1.98
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 27.07

Current Ratio	27.07
Quick Ratio	22.57
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -97.99% and return on invested capital (ROIC) is -62.65%.

Return on Equity (ROE)	-97.99%
Return on Assets (ROA)	-56.59%
Return on Invested Capital (ROIC)	-62.65%
Return on Capital Employed (ROCE)	-87.87%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$1.82M
Employee Count	3
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -42.46% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-42.46%
50-Day Moving Average	0.61
200-Day Moving Average	0.90
Relative Strength Index (RSI)	41.47
Average Volume (20 Days)	91,275

Short Selling Information

The latest short interest is 198,425, so 0.93% of the outstanding shares have been sold short.

Short Interest	198,425
Short Previous Month	181,710
Short % of Shares Out	0.93%
Short % of Float	1.60%
Short Ratio (days to cover)	0.15

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-5.57M
Pretax Income	-5.45M
Net Income	-5.45M
EBITDA	-5.41M
EBIT	-5.57M
Earnings Per Share (EPS)	-$0.30

Balance Sheet

The company has $4.49 million in cash and n/a in debt, with a net cash position of $4.49 million or $0.21 per share.

Cash & Cash Equivalents	4.49M
Total Debt	n/a
Net Cash	4.49M
Net Cash Per Share	$0.21
Equity (Book Value)	6.34M
Book Value Per Share	0.30
Working Capital	5.19M

Cash Flow

Operating Cash Flow	-3.44M
Capital Expenditures	n/a
Depreciation & Amortization	160,000
Net Borrowing	3.60M
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kairos Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-62.27%
Shareholder Yield	-62.27%
Earnings Yield	-43.72%
FCF Yield	n/a

Analyst Forecast

The average price target for Kairos Pharma is $10.50, which is 1,678.46% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.50
Price Target Difference	1,678.46%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1